Advanced Hepatocellular Cancer: the Current State of Future Research
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Advanced Hepatocellular Cancer: the Current State of Future Research
Authors
Keywords
Hepatocellular carcinoma, Targeted therapy, Sorafenib, Angiogenic, Doxorubicin, Cabozantinib, Tivantinib, Everolimus, Pegylated arginine deiminase (ADI-PEG 20), Tremelimumab, Nivolumab, MEDI4736, Immunotherapy
Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 17, Issue 8, Pages -
Publisher
Springer Nature
Online
2016-06-26
DOI
10.1007/s11864-016-0415-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 1058PDA PHASE I MULTI-ARM DOSE-EXPANSION STUDY OF THE ANTI-PROGRAMMED CELL DEATH-LIGAND-1 (PD-L1) ANTIBODY MEDI4736: PRELIMINARY DATA
- (2017) N.H. Segal et al. ANNALS OF ONCOLOGY
- Selection of Patients with Hepatocellular Carcinoma for Sorafenib
- (2017) Ghassan K. Abou-Alfa Journal of the National Comprehensive Cancer Network
- Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone
- (2016) Karen T. Brown et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
- (2015) James J. Harding et al. CANCER
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus
- (2015) H. Huynh et al. MOLECULAR CANCER THERAPEUTICS
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Response Regulation in the Tumor Microenvironment by Hypoxia
- (2015) Sara Labiano et al. SEMINARS IN ONCOLOGY
- Targeted therapy for hepatocellular carcinoma: novel agents on the horizon
- (2015) Melchiorre Cervello et al. Oncotarget
- A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma
- (2014) Jennifer J. Knox et al. INVESTIGATIONAL NEW DRUGS
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates
- (2013) R. K. Kelley et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
- (2013) R. Katayama et al. CANCER RESEARCH
- Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
- (2013) L. Goyal et al. CLINICAL CANCER RESEARCH
- Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
- (2013) Jordi Bruix et al. EUROPEAN JOURNAL OF CANCER
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia
- (2013) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
- (2013) Jie Sheng Chu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?
- (2013) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
- (2013) Jeong Heo et al. NATURE MEDICINE
- Epigenetic Upregulation of HGF and c-Met Drives Metastasis in Hepatocellular Carcinoma
- (2013) Olorunseun O. Ogunwobi et al. PLoS One
- Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma
- (2012) Han Chong Toh et al. CANCER
- Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib
- (2012) A. Lachenmayer et al. CLINICAL CANCER RESEARCH
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
- (2012) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- (2012) Armando Santoro et al. LANCET ONCOLOGY
- Exome sequencing of hepatitis B virus–associated hepatocellular carcinoma
- (2012) Jian Huang et al. NATURE GENETICS
- Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators
- (2012) Akihiro Fujimoto et al. NATURE GENETICS
- Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma
- (2012) Cécile Guichard et al. NATURE GENETICS
- Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2012) V. Boige et al. ONCOLOGIST
- Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial
- (2012) A.O. Kaseb et al. ONCOLOGY
- An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma
- (2012) David J. Pinato et al. Translational Research
- The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy
- (2012) Asís Palazón et al. Cancer Discovery
- Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma
- (2011) Hung Huynh et al. ANGIOGENESIS
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer
- (2011) Philip A. Philip et al. CANCER
- Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2011) J.-W. Park et al. CLINICAL CANCER RESEARCH
- Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
- (2011) Masatoshi Kudo et al. EUROPEAN JOURNAL OF CANCER
- TACE and Sorafenib: A Good Marriage?
- (2011) Ghassan K. Abou-Alfa JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma
- (2011) Timothy M. Pawlik et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy
- (2011) Jeong Heo et al. MOLECULAR THERAPY
- Hepatocellular Carcinoma
- (2011) Hashem B. El-Serag NEW ENGLAND JOURNAL OF MEDICINE
- A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients
- (2010) T-S Yang et al. BRITISH JOURNAL OF CANCER
- Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma
- (2010) Ghassan K. Abou-Alfa et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma
- (2010) Evan S. Glazer et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model
- (2010) Richard S. Finn et al. LIVER INTERNATIONAL
- Continuous Administration of Sorafenib in Combination with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Results of a Phase I Study
- (2010) J.-F. Dufour et al. ONCOLOGIST
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study
- (2009) Johannes Lammer et al. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
- MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells
- (2009) Alessandro Salvi et al. FEBS Journal
- New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication
- (2009) K. Himmelsbach et al. GUT
- Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301
- (2009) Antonius A. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma
- (2009) Melanie B. Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
- (2009) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
- (2009) Sandrine Faivre et al. LANCET ONCOLOGY
- Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization
- (2008) B. Wang et al. ACTA RADIOLOGICA
- Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
- (2008) D. Y. Chiang et al. CANCER RESEARCH
- Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
- (2008) H. Huynh et al. CLINICAL CANCER RESEARCH
- Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma
- (2008) Ai-Wu Ke et al. HEPATOLOGY
- Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2008) Abby B. Siegel et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started